Drug intelligence / Profile preview

NVG-555

Development stage: Preclinical
Lead developer: NovalGen
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

NVG-555 is a bispecific checkpoint inhibitor (CPI) being developed by Novalgen Ltd. for the treatment of neoplasms, hemic and lymphatic diseases, and immune system disorders. As a bispecific antibody, NVG-555 is engineered to simultaneously antagonize two independent immune checkpoint pathways, potentially providing a synergistic therapeutic effect compared to single-pathway inhibition. The drug is currently in the preclinical or early development stage within Novalgen's immunotherapy pipeline, targeting various cancers and immune-mediated conditions.

Targets

Checkpoint (Immune checkpoints)

Beyond the preview

Go deeper on NVG-555.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NVG-555.

Explore the full profile